Risk adapted therapy for newly diagnosed multiple myeloma delivered through local cytogenetic laboratories in a National Clinical Trial: UKMRA RADAR study

Risk adapted therapy for newly diagnosed multiple myeloma delivered through local cytogenetic laboratories in a National Clinical Trial: UKMRA RADAR study

Abstract The UKMRA RADAR study is a phase II/III clinical trial for newly diagnosed multiple myeloma patients eligible for autologous stem cell transplant. It offers a risk‐adapted approach with the addition of isatuximab for genetically high‐risk patients, evaluated using local cytogenetics laborat...

Full description

Saved in:
Bibliographic Details
Main Authors: Dipal Mehta, Robert Cicero, Laura Chiecchio, Samir Asher, Martin Kaiser, Sarah Gooding, Kara‐Louise Royle, Catherine Olivier, Doina Levinte, Charlotte Kennaway, Karthik Ramasamy, Kwee Yong, Matthew Jenner
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:eJHaem
Subjects:
cytogenetics
multiple myeloma
risk stratification
Online Access:https://doi.org/10.1002/jha2.1015
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/jha2.1015

Similar Items